The objective of this application is to establish a reference laboratory and standard protocols for evaluation of potential therapeutic agents for sickle cell disease. This proposed reference laboratory is designed to facilitate rapid, efficient, and economical evaluation of agents that may be beneficial in the treatment of patients with sickle cell disease. This proposal represents the combined efforts of three different laboratories that are actively engaged in research related to sickle cell disease. We will first examine the effect of candidate agents on cell sickling, functional properties of hemoglobin, and the existence of adverse effects, such as hemoglobin oxidation or red blood cell hemolysis. Additional studies will be carried out to determine effects of candidate drugs on the membrane transport properties and cell volume control, and on the interaction between sickle cells and endothelial cells. The information gathered from the studies in vitro will be used to determine which compounds to evaluate in vivo using various lines of transgenic mice which produce human sickle hemoglobin (Hb S mouse models) including the recently developed Hb S-F mice, which produce human Hb S and Hb F exclusively. Transgenic Hb S mouse models are particularly useful to study effects of new therapeutic approaches for patients with sickle cell disease, such as gene therapy, stimulation of Hb F synthesis, hydration of red blood cells by membrane-acting agents and inhibition of endothelial adhesion. The availability of transgenic sickle mice will allow testing in vivo of these potential approaches and provide important information for the feasibility and design of human trials. Evaluation of therapeutic agents in vivo is essential since many drugs that prevent sickling in vitro can not be used in vivo because of toxicity or inability to reach a therapeutic concentration. This reference laboratory will also evaluate the effects of combined therapy of drugs with different mechanisms of action, such as hydroxyurea and membrane active agents. We will study several agents in combination with hydroxyurea to determine the optimal dosage of each drug required to achieve a significant therapeutic effect with the least toxicity. This reference laboratory will offer its services to any investigator with a potential candidate drug for treatment of sickle cell disease and will provide an economical and efficient system to evaluate new therapies for patients with sickle cell disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
5U24HL058930-02
Application #
2771613
Study Section
Special Emphasis Panel (ZHL1-CSR-F (M1))
Project Start
1997-09-30
Project End
2001-08-31
Budget Start
1998-09-01
Budget End
1999-08-31
Support Year
2
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Kiryu, Shigeru; Sundaram, Tessa; Kubo, Shigeto et al. (2008) MRI assessment of lung parenchymal motion in normal mice and transgenic mice with sickle cell disease. J Magn Reson Imaging 27:49-56
Uematsu, Hidemasa; Takahashi, Masaya; Hatabu, Hiroto et al. (2007) Changes in T1 and T2 observed in brain magnetic resonance imaging with delivery of high concentrations of oxygen. J Comput Assist Tomogr 31:662-5
Obata, Kazuo; Mattiello, Julian; Asakura, Kenji et al. (2006) Exposure of blood from patients with sickle cell disease to air changes the morphological, oxygen-binding, and sickling properties of sickled erythrocytes. Am J Hematol 81:26-35
Abdulmalik, Osheiza; Safo, Martin K; Chen, Qiukan et al. (2005) 5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. Br J Haematol 128:552-61
Asakura, Toshio; Asakura, Kenji; Obata, Kazuo et al. (2005) Blood samples collected under venous oxygen pressure from patients with sickle cell disease contain a significant number of a new type of reversibly sickled cells: constancy of the percentage of sickled cells in individual patients during steady state. Am J Hematol 80:249-56
Zhang, Chaojie; Li, Xiang; Lian, Lurong et al. (2004) Anti-sickling effect of MX-1520, a prodrug of vanillin: an in vivo study using rodents. Br J Haematol 125:788-95
Iyamu, Efemwonkiekie W; Adunyah, Samuel E; Fasold, Hugo et al. (2003) Combined use of nonmyelosuppressive nitrosourea analogues with hydroxyurea in the induction of F-cell production in a human erythroleukemic cell line. Exp Hematol 31:592-600
Iyamu, Efemwonkiekie W; Turner, Ernest A; Asakura, Toshio (2003) Niprisan (Nix-0699) improves the survival rates of transgenic sickle cell mice under acute severe hypoxic conditions. Br J Haematol 122:1001-8
Iyamu, Efemwonkiekie W; Turner, Ernest A; Asakura, Toshio (2002) In vitro effects of NIPRISAN (Nix-0699): a naturally occurring, potent antisickling agent. Br J Haematol 118:337-43
Iyamu, W E; Lian, L; Asakura, T (2001) Pharmacokinetic profile of the anti-sickling hydroxyurea in wild-type and transgenic sickle cell mice. Chemotherapy 47:270-8

Showing the most recent 10 out of 13 publications